Survey to Assess Physicians' Knowledge of Exjade Posology and Biological Monitoring Recommendations as Described in the Educational Materials

NCT06215287 | Completed

• 2 other identifiers: CICL670A2429EUPAS104950
• Study Type: observational
• Target: 400
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of this survey is to assess the knowledge of HCPs in relation to the recommended posology and biological monitoring for Exjade, based on the current locally valid Exjade educational materials (including the physician's reference checklist)

Conditions

Chronic Iron Overload

Keywords

Physician Survey,; PAS,; Deferasirox

Outcome Measures

Primary Outcomes (1)

• Mean percentage of correct responses related to knowledge of posology and biological monitoring recommendations as described in the Exjade EU Summary of Product Characteristics (SmPC)

  The primary endpoint is a composite endpoint based on the percentages of HCPs with correct responses to all questions included in the composite regarding the below information: * Administration and dosing of Exjade (deferasirox) FCT * Biological monitoring

  Through study completion, an average of 6 months.

Study Arms (1)

Exjade Prescribers/HCP receiving Educational Materials

HCPs prescribing Exjade in the EU/EEA provided with Exjade Educational Materials

Other: Physician survey

Interventions

Physician survey OTHER

Survey to assess physicians' knowledge of Exjade posology and biological monitoring recommendations as described in the Educational Materials

Exjade Prescribers/HCP receiving Educational Materials

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Exjade (deferasirox) prescribers

You may qualify if:

• Must provide consent for participation
• Must spend ≥50% of time in direct patient care
• Have treated patients with transfusional iron overload or non-transfusion-dependent thalassemia with chelation therapy during the last 12 months.
• Have prescribed Exjade and/or generic deferasirox within the last 12 months.

You may not qualify if:

• Physicians meeting the following criterion will not be eligible to take the survey:
• Currently employed by a pharmaceutical company, health care company, market research company, advertising agency, or government agency involved in pharmaceutical research or marketing.

Sponsors & Collaborators

• Novartis Pharmaceuticals: lead

Study Sites (1)

Novartis Investigative Site

Basel, Switzerland

Location

Study Officials

• Novartis Pharmaceuticals

  Novartis Pharmaceuticals

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 10, 2024
• First Posted: January 22, 2024
• Study Start: January 12, 2024
• Primary Completion: February 15, 2024
• Study Completion: February 15, 2024
• Last Updated: May 17, 2024

Record last verified: 2024-05

Data Sharing

• IPD Sharing: Will not share

Locations

CH (1)